Page results
-
A smartphone app that identifies severe neonatal jaundice could provide a cheaper alternative to expensive screening procedures, according to a study by UCLH, UCL and the University of Ghana.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
The Clinical and Research Informatics Unit at UCLH consists of a team of clinicians, researchers, software developers, business intelligence analysts and data scientists working together to develop a robust environment for the analysis of clinical data.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
A pioneering breast cancer therapy developed by UCLH and UCL, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease.
-
A healthcare project aimed at homeless people and delivered by UCLH has been specially commended in this year’s London Homelessness Awards.
-
Sarah, Duchess of York, and Their Royal Highnesses Princess Beatrice and Princess Eugenie met with staff and young people in a video call to formally open the specialist haematology ward for young adults in the University College Hospital Grafton Way Building last week (Monday 11 July).
-
As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.
File results
-
FOI/2024/0393 - Translation service/ communication spend
-
FOI/2024/0385 - Immunoglobulin vials (by brands) distributed to patients
-
FOI/2024/0381 - Proton Beam Therapy Centre material use, architectural technology and performance
-
FOI/2024/0380 - Appraisal review/ Responsible Officer/ Revalidation Officer
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust